Vistagen Therapeutics (VTGN) Current Assets (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Current Assets of $46.9 million for Q1 2026, down 25.78% sequentially from $63.2 million in Q4 2025, and down 42.81% YoY from $82.1 million in Q1 2025.
Vistagen Therapeutics (VTGN) Current Assets (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Current Assets for 14 years, with the latest figure at $46.9 million in Q1 2026.
- Quarterly Current Assets fell 42.81% year-over-year to $46.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.9 million (down 42.81% YoY) and the FY2026 annual result came in at $46.9 million, down 42.81% from the prior year.
- Current Assets declined to $46.9 million in Q1 2026 per VTGN's latest filing, from $63.2 million in the prior quarter.
- Over five years, Current Assets peaked at $128.1 million in Q4 2023 and troughed at $11.6 million in Q2 2023.
- A 5-year average of $67.3 million and a median of $66.7 million in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2024: Current Assets sank 78.95% in 2023, then surged 857.25% in 2024.
- Over 5 years, Current Assets stood at $26.1 million in 2022, then soared by 391.66% to $128.1 million in 2023, then declined by 29.8% to $89.9 million in 2024, then dropped by 29.68% to $63.2 million in 2025, then declined by 25.78% to $46.9 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $46.9 million, $63.2 million, and $78.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 1.76 Bn |
| 10 | Vistagen Therapeutics | 10.67 Mn | 10.67 Mn | - | 34.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.94 Mn |
| Dec 31, 2025 | 63.25 Mn |
| Sep 30, 2025 | 78.93 Mn |
| Jun 30, 2025 | 66.72 Mn |
| Mar 31, 2025 | 82.08 Mn |
| Dec 31, 2024 | 89.94 Mn |
| Sep 30, 2024 | 99.95 Mn |
| Jun 30, 2024 | 110.84 Mn |
| Mar 31, 2024 | 120.67 Mn |
| Dec 31, 2023 | 128.11 Mn |
| Sep 30, 2023 | 39.08 Mn |
| Jun 30, 2023 | 11.58 Mn |
| Mar 31, 2023 | 17.51 Mn |
| Dec 31, 2022 | 26.06 Mn |
| Sep 30, 2022 | 36.91 Mn |
| Jun 30, 2022 | 54.99 Mn |
| Mar 31, 2022 | 71.00 Mn |
| Dec 31, 2021 | 86.77 Mn |
| Sep 30, 2021 | 96.44 Mn |
| Jun 30, 2021 | 99.83 Mn |